NASDAQ:CDLXCardlytics Stock Price, Forecast & News

Cardlytics' stock was trading at $45.83 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CDLX shares have increased by 46.0% and is now trading at $66.89. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardlytics in the last year. There are currently 1 sell rating, 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Cardlytics.

Cardlytics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Cardlytics.

Cardlytics Inc (NASDAQ:CDLX) issued its earnings results on Monday, May, 11th. The company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.09. The firm had revenue of $45.51 million for the quarter, compared to analyst estimates of $42.97 million. Cardlytics had a negative net margin of 11.08% and a negative return on equity of 19.42%. The company's revenue was up 26.5% compared to the same quarter last year. During the same quarter last year, the business posted ($0.23) earnings per share. View Cardlytics' earnings history.

Cardlytics issued an update on its first quarter 2020 After-Hours earnings guidance on Tuesday, March, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $43.5-46.5 million, compared to the consensus revenue estimate of $52.77 million.

7 brokers have issued twelve-month price targets for Cardlytics' stock. Their forecasts range from $26.00 to $55.00. On average, they expect Cardlytics' share price to reach $48.50 in the next twelve months. This suggests that the stock has a possible downside of 27.5%. View analysts' price targets for Cardlytics.

News headlines about CDLX stock have trended positive recently, InfoTrie reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cardlytics earned a news impact score of 2.7 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutCardlytics.

Some companies that are related to Cardlytics include 58.com (WUBA), Weibo (WB), GDS (GDS), InterXion (INXN), Livongo Health (LVGO), Switch (SWCH), Medallia (MDLA), HUYA (HUYA), Pluralsight (PS), SVMK (SVMK), Tripadvisor (TRIP), DouYu International (DOYU), Sabre (SABR), Internet Initiative Japan (IIJIY) and 21Vianet Group (VNET). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardlytics investors own include Alibaba Group (BABA), Trade Desk (TTD), Advanced Micro Devices (AMD), NVIDIA (NVDA), Caterpillar (CAT), Roku (ROKU), Micron Technology (MU), Netflix (NFLX), Square (SQ) and Walt Disney (DIS).

(CDLX) raised $76 million in an IPO on Friday, February 9th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. BofA Merrill Lynch and J.P. Morgan served as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey, Raymond James and KeyBanc Capital Markets were co-managers.

Cardlytics trades on the NASDAQ under the ticker symbol "CDLX."

Cardlytics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include CAS Investment Partners LLC (14.65%), Wellington Management Group LLP (4.69%), BlackRock Inc. (4.43%), Grantham Mayo Van Otterloo & Co. LLC (3.00%), JS Capital Management LLC (2.02%) and Frontier Capital Management Co. LLC (2.05%). Company insiders that own Cardlytics stock include Aimia Inc, Andrew Christiansen, Bryce Youngren, Clifford Sosin, David Leslie Adams, David Thomas Evans, John V Balen, Kirk Somers, Lynne Marie Laube, Mark A Johnson, Polaris Venture Management Co, Scott D Grimes and Tony Weisman. View institutional ownership trends for Cardlytics.

CDLX stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Deutsche Bank AG, Driehaus Capital Management LLC, BNP Paribas Arbitrage SA, Invesco Ltd., Morgan Stanley, Morgan Stanley, and Nuveen Asset Management LLC. Company insiders that have sold Cardlytics company stock in the last year include Aimia Inc, Andrew Christiansen, Bryce Youngren, David Leslie Adams, David Thomas Evans, Kirk Somers, Lynne Marie Laube, Mark A Johnson, Polaris Venture Management Co, Scott D Grimes, and Tony Weisman. View insider buying and selling activity for Cardlytics.

CDLX stock was purchased by a variety of institutional investors in the last quarter, including CAS Investment Partners LLC, JPMorgan Chase & Co., Grantham Mayo Van Otterloo & Co. LLC, THB Asset Management, Rockefeller Capital Management L.P., Harspring Capital Management LLC, Frontier Capital Management Co. LLC, and Lord Abbett & CO. LLC. Company insiders that have bought Cardlytics stock in the last two years include Clifford Sosin, and John V Balen. View insider buying and selling activity for Cardlytics.

Shares of CDLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CDLX stock can currently be purchased for approximately $66.89.

Cardlytics has a market capitalization of $1.80 billion and generates $210.43 million in revenue each year. The company earns $-17,140,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis.

The official website for Cardlytics is www.cardlytics.com.

Cardlytics' mailing address is 675 PONCE DE LEON AVENUE NE SUITE 6000, ATLANTA GA, 30308. The company can be reached via phone at 888-798-5802 or via email at [email protected]